Tamara Mishchenko

Tamara Mishchenko

Auto-generated profile, based on publicly available information

Tamara Mishchenko

V.N. Karazin Kharkiv National University of the Ministry of Education and Science of Ukraine, Kharkiv, Ukraine; State Institution «P.V. Voloschyn Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
ASA. A. Skoromets
A. A. Skoromets
AGA. B. Guekht
A. B. Guekht
DGD. V. Galanov
D. V. Galanov
ODO. A. Danilenko
O. A. Danilenko
EBE. R. Barantsevich
E. R. Barantsevich
SGS. G. Guseinov
S. G. Guseinov
The prospective multicenter open noncomparative pharmaco-epidemiological observational project on the use of mydocalm in real clinical practice has been completed in 2013. The project has been performed in 2090 clinical/rehabilitation settings in 284 cities of 13 countries using the results of 35,383 patients. The project aimed to assess the safety of treatment (percentage of patients with adverse-effects) and pain relieving efficacy as well as patient's satisfaction with the treatment. In total, 6603 (19%) adverse-effects were recorded. Their severity was evaluated as mild in 84,48%, no serious adverse-effects were noted. The high efficacy of mydocalm in the treatment of pain syndromes with the muscle spasm has been demonstrated. The high level of tolerability and absence of the clinically significant increase of adverse effects in the combination with nonsteroidal anti-inflammatory drugs have been confirmed.

30 August 2022 in Psychiatry, Neurology and Medical Psychology
Verified
Journal Article
Open access
PDF file
TMT. S. Mishchenko
T. S. Mishchenko
VMV. M. Mishchenko
V. M. Mishchenko
KKK. V. Kharina
K. V. Kharina
HLH.V. Linska
H.V. Linska
Actuality: Increasing the frequency of hypertension among the young population is a socially significant problem. The insidiousness of hypertension in young people is that it has the character of a disease with few symptoms. Since hypertension plays one of the main roles in the pathogenesis of chronic disorders of cerebral blood circulation, including both arterial and venous systems, the search for pathogenetically determined medicinal approaches to the elimination of cerebrovascular disorders, especially at a young age, continues. The purpose of the study: to study the effectiveness, tolerability and safety of the combination of Flego and Cognitium in young patients with chronic cerebral ischemia (CMI) on the background of hypertension. Methods: clinical-neurological, psychodiagnostic (asthenic state scale (ASS), anxiety scores according to the Spielberger-Hanin scale and Beck depression scale, Montreal scale of cognitive function assessment (MoCA)), ultrasound examination, general scale of clinical impression, statistical. Results: 52 patients (28 men and 24 women) at a young age with AMI on the background of hypertension were examined. The median age of the examined patients was (37.7 ± 4.6) years; among them, 23 patients suffered from hypertension of the 1st century. and 29 patients with hypertension of the second stage. Patients were randomly divided into two groups - the first - 23 (44.2%) patients (received only hypotensive drugs), the second - 29 (55.8%) patients (in addition to the standard hypotensive therapy received a combination of Phlego and Cognitium). Dynamic monitoring of patients after 2 months of treatment did not show significant changes in the distribution structure of objective clinical and neurological symptoms. However, positive dynamics of indicators of cognitive functions and the psychoemotional state of the subjects were observed, as well as a statistically significant decrease in the blood flow rate in the direct sinus at the end of the 2-month course using the combination of Phlego and Cognitium (decreased from 36.27±2.84 cm/s to 25.65±1.47 cm/s.). Conclusions: The introduction of the combination of Phlego and Cognitium into the treatment of young patients with arterial hypertension and chronic brain ischemia had a positive effect on the subjective state, on indicators of asthenia, emotional and cognitive state of the patients. A significant positive effect was noted in the dynamics of venous blood flow indicators (speed of blood flow in the direct sinus). Such treatment was well tolerated by patients, had few side effects and was combined with other drugs

29 December 2022 in Psychiatry, Neurology and Medical Psychology
Verified
Journal Article
Open access
PDF file
TMT. S. Mishchenko
T. S. Mishchenko
VBVictoria Bokatueva
Victoria Bokatueva
VMV. M. Mishchenko
V. M. Mishchenko
KKK. V. Kharina
K. V. Kharina
Actuality: Arterial hypertension (AH) is one of the most common diseases among diseases of the circulatory system and, together with other cardiovascular diseases, ranks first in the world and in Ukraine in terms of mortality rates. About 45% of patients do not know that they have hypertension. The scale of this problem in the world is evidenced by the fact that hypertension is found in every third adult. This disease occurs more often in the elderly, but its development often begins at a young age, and sometimes even in childhood. The intensive development of neuroimaging methods (CT and MRI) in recent decades makes it possible to detect various changes in the brain at early preclinical stages, which is of great importance for the implementation of adequate differentiated primary prevention of the development and progression of cerebrovascular disease and such unpleasant manifestations as cognitive deficits, dementia and ischemic stroke. The purpose of the study: to reveal the nature of structural changes in the brain in young patients with clinically confirmed hypertension. Material and methods: a study of structural changes in the brain was conducted based on the MRI examination data (1.5 T) of 54 young patients (18-44 years old) with hypertension of various degrees. Statistical analysis was carried out by the IBM SPSS Statistics 20 license program using the criterion of agreement with the test of static significance (Fisher's exact test -F). Results: Differences in brain structural changes were obtained in patients depending on the degree of hypertension. A significant difference according to the χ² criterion (р<0.05) was found in the frequency of occurrence of mixed, external and internal hydrocephalus in patients with hypertension of the first and second century. Differences in the incidence of external and internal hydrocephalus in patients with AH I and AH III, AH II and AH III not detected by the χ² criterion (p< 0.05). There are differences in the frequency of leukoaraiosis of the 0th, 1st, 2nd, and 3rd stages. according to the Fazekas scale between groups of patients with 1st stage hypertension, 2nd stage hypertension, and 3rd stage hypertension reliable according to the χ² criterion (р< 0.05). Differences in the frequency of lacunar foci at different degrees of hypertension were not reliably detected. The analysis of the results of the assessment of structural changes of the brain by age showed that the main differences in the occurrence of mixed and external hydrocephalus are characteristic of all age groups. There is no difference in the frequency of internal hydrocephalus, mild and moderate leukoaraiosis in the groups of men and women. The frequency of occurrence of mixed, external hydrocephalus, the absence of leukoaraiosis and the presence of severe draining leukoaraiosis (in men, the severity of these changes prevails) is significantly different. No difference in the frequency of lacunar foci was found in the groups of men and women. Conclusions: Thus, hypertension is an age-dependent disease. No differences were found in the frequency of complaints of noise in the head, decreased attention and cognitive activity, sleep disturbances, and gender differences in the examined patients with hypertension of various degrees of severity. The main structural changes of the brain in the examined patients are various types of hydrocephalic manifestations, signs of leukoaraiosis (characteristic for the older age of 36-44 years) of one degree or another. Some gender specific features of brain structural changes in the examined patients were revealed (increased manifestations of hydrocephalus syndrome in men and absence of leukoaraiosis in them compared to women).

30 December 2024 in Psychiatry, Neurology and Medical Psychology
Verified
Journal Article
Open access
PDF file
VMV.м. Mishchenko
V.м. Mishchenko
TMT.S. Mishchenko
T.S. Mishchenko
VBV.V. Bokatueva
V.V. Bokatueva
KKK.V. Kharina
K.V. Kharina
VSV.V. Sokolik
V.V. Sokolik
Background. Recent studies have shown that COVID-19 infection leads to the development of neurological diseases or causes exacerbation and progression of existing neurological diseases. However, despite the large number of studies conducted on this issue, our knowledge of the mechanisms of development and progression of neurological disorders is far from complete and requires further study. This is especially true for cerebrovascular diseases (CVD), the prevalence of which has increased significantly during and after the COVID-19 pandemic. Purpose – of our study was to investigate the clinical and pathogenetic mechanisms of CVD development in patients with COVID-19, to identify risk groups and biomarkers of their development and progression. Materials and Methods. We examined 48 patients aged 42 to 74 years with CVD. The main group consisted of patients with clinical and paraclinical signs of chronic cerebral ischaemia who had documented COVID-19. The comparison group (control) consisted of 48 patients of the same age with chronic cerebral ischaemia without COVID-19. It was found that the structure of clinical manifestations of chronic cerebral ischaemia was dominated by asthenic, cephalgic, vestibulo-ataxic syndromes, cognitive and psychoemotional disorders, and severe autonomic disorders. Results. The most significant factors in the development of CVD in patients after COVID-19 are age, history of arterial hypertension, diabetes mellitus, obesity, severity of the acute period of COVID-19 and vascular endothelial condition. Conclusion. On the basis of the conducted studies, the mechanisms of CVD formation in patients with COVID-19 were proposed. The presence of cardiovascular risk factors in patients and the prolonged course of the acute period of coronavirus infection lead to the development of neuroinflammation, coagulation disorders, endothelial dysfunction, cerebral hypoperfusion, and, as a result, the development of acute and chronic cerebrovascular disorders.

31 May 2023 in ScienceRise: Medical Science
Verified
Journal Article
Open access
PDF file
IGIryna Govbakh
Iryna Govbakh
TMTamara Mishchenko
Tamara Mishchenko
The aim of the study was to investigate the characteristics of the spread of hereditary motor and sensory neuropathy type 1A in the Sumy region, in terms of administrative units and specific ethnic groups of the population. Materials and methods. An epidemiological study of hereditary motor and sensory neuropathy (HMSN) type 1A in the Sumy region was conducted based on patient referrals to various healthcare facilities from 2014 to 2017. The prevalence of HMSN in the Sumy region was studied using an epidemiological approach. The prevalence rate of HMSN was calculated for different administrative units of the Sumy region, as well as for specific ethnic groups of the population. Results. The study registered 67 patients with hereditary motor and sensory neuropathy type 1A in the Sumy region. The prevalence rate of hereditary motor and sensory neuropathy type 1A in the Sumy region was 5.96 per 100,000 population. Of the HMSN patients, 47.8 % (32 individuals) resided in urban areas, while 52.2 % (35 individuals) lived in rural areas. In terms of gender distribution, 59.7 % (40 individuals) were female, and 40.3 % (27 individuals) were male. Most patients were of Ukrainian ethnicity (77.6 %), followed by Russians (20.9 %). Belarusians accounted for 1.5 % of HMSN patients in the Sumy region. Among other ethnic groups present in the Sumy region, HMSN type 1A was not detected. Conclusions. Hereditary motor and sensory neuropathy type 1A is unevenly distributed in the Sumy region. The heterogeneous distribution of the disease is primarily attributed to the characteristics of settlement in specific geographic regions, which have led to the formation of territorial, national, and religious isolates with the accumulation of genetically heterogeneous types in these populations, resulting in an increased genetic burden

29 March 2024 in Psychiatry, Neurology and Medical Psychology
Verified
Journal Article
Open access
PDF file
TMT.S. Mishchenko
T.S. Mishchenko
LZLiudmyla Zabrodina
Liudmyla Zabrodina
VMV.M. Mishchenko
V.M. Mishchenko
YBY.V. Bovt
Y.V. Bovt
Relevance. Chronic insomnia is one of the most common forms of nighttime sleep disorders. It leads to a decrease in human performance, the development of social maladjustment, and even changes in the personal sphere. Chronic insomnia can become a trigger for decompensation of somatic, neurological and mental diseases, which determines the need to find ways to overcome it. Objective. To determine the efficacy and safety of the dietary supplement Alpha-Melatonin Relax in the treatment of chronic insomnia in patients with chronic cerebral ischemia. Materials and methods. The study involved 30 patients (18 women and 12 men) with chronic cerebral ischemia of stage I and II, the average age of which was 46.12 ± 4.98 years. The course of treatment consisted of 30 days of taking Alpha-Melatonin Relax, 1–2 tablets 30–60 minutes before bedtime. Clinical and neurological symptoms were assessed and tested using the Pittsburgh Sleep Quality Index (PSQI) questionnaire, Epworth Daytime Sleepiness Scale, and the Hospital Anxiety and Depression Scale (HADS) in dynamics. Results and their discussion. The study results showed that 30-day administration of Alpha-Melatonin Relax provided a significant p≤0.05 improvement in the subjective assessment of the quality of night sleep, a decrease in the time to fall asleep, an increase in sleep duration, a decrease in the severity of emotional disorders and daytime dysfunction. Clinical and neurological follow-up of patients during the treatment course revealed a significant reduction in the severity of chronic insomnia, asthenia, and anxiety-depressive symptoms, which allows us to recommend the use of the dietary supplement Alpha-Melatonin Relax in clinical practice. Conclusions. Based on the data of a clinical-neurological and psychodiagnostic study, the statistically significant effectiveness of the dietary supplement AlphaMelatonin Relax in correcting the symptoms of chronic insomnia in patients with the initial stages of chronic brain ischemia has been proven.